| Literature DB >> 31428160 |
Bhuvan Saud1,2, Rajani Malla1, Kanti Shrestha2.
Abstract
Stem cell has immense potential in regenerative cellular therapy. Mesenchymal stem cells (MSCs) can become a potential attractive candidate for therapy due to its remarkable ability of self-renewal and differentiation into three lineages, i.e., ectoderm, mesoderm, and endoderm. Stem cell holds tremendous promises in the field of tissue regeneration and transplantation for disease treatments. Globally, medicinal plants are being used for the treatment and prevention of a variety of diseases. Phytochemicals like naringin, icariin, genistein, and resveratrol obtained from plants have been extensively used in traditional medicine for centuries. Certain bioactive compounds from plants increase the rate of tissue regeneration, differentiation, and immunomodulation. Several studies show that bioactive compounds from plants have a specific role (bioactive mediator) in regulating the rate of cell division and differentiation through complex signal pathways like BMP2, Runx2, and Wnt. The use of plant bioactive phytochemicals may also become promising in treating diseases like osteoporosis, neurodegenerative disorders, and other tissue degenerative disorders. Thus, the present review article is aimed at highlighting the roles and consequences of plant extracts on MSCs proliferation and desired lineage differentiations.Entities:
Year: 2019 PMID: 31428160 PMCID: PMC6681598 DOI: 10.1155/2019/7513404
Source DB: PubMed Journal: Stem Cells Int Impact factor: 5.443
Figure 1MSCs isolated from different sources derived from adult and fetal tissues. MSCs must be positive for cluster of differentiation CD90, CD75, and CD105 and negative for CD34, CD45, CD14, CD11b, CD79a, CD19, and HLA-DR according to ISCT criteria [4]. Bioactive compound derived from plants regulates MSC gene expression, which may be responsible for the cellular proliferation and multilineage differentiation into osteocyte, muscle cells, nerve cells [86, 88], adipocyte [89], and chondrocyte [90].
Effect of plant extract on MSC proliferation.
| Plant | MSC source | Mechanism of action | References |
|---|---|---|---|
|
| hBMSCs | 20 | [ |
|
| hAD-MSCs and CB-MSCs | 25% and 20% increase cell proliferation rate, and TGF- | [ |
|
| hDP-MSCs and BM-MSC | Induces MSC proliferation and reduces doubling time (DT) at 10 | [ |
|
| hAD-MSCs | 5 and 10 mg/ml concentrations stimulate proliferation. Increases the catalase (CAT) activity and SOD2, CAT, and GPx gene expression | [ |
|
| hBM-MSC | Increases significant level of proliferation at concentration 10-50 | [ |
|
| h-Dental pulp (DP) and BM-MSCs | Reduces the doubling time (DT) at 10 | [ |
| ZD-I: TCM | Telomerized hMSCs | 0.78–25 | [ |
|
| hBM-MSC | 0–200 | [ |
|
| hBM-MSC | Proliferation activity is seen with a dose of 5 | [ |
|
| Wistar rat BM-MSCs | 300 | [ |
|
| h-AD MSCS and CB-MSCs | Proliferation promotes by ERK-dependent cytokine production | [ |
|
| hBM-MSCs | 0.5 to 5 | [ |
|
| hBM-MSCs | 25 mg/l increases the cell proliferation by 30% | [ |
Effect of plant extracts on MSC differentiation.
| Plant extracts | MSC source | Differentiate into | Mechanism of action | References |
|---|---|---|---|---|
| Fructus Ligustri Lucidi (FLL) | — | Osteogenic | Increases ALP activity, expression of osteogenesis-stimulating genes, | [ |
| Fructus Ligustri Lucidi (FLL) | Rat MSC | Osteogenic | Increases ALP activity, osteoprotegerin- (OPG-) to-receptor activator for nuclear factor- | [ |
| China Herba epimedii | h BM-MSC | Osteogenic | Increases ALP activity and enhances mRNA expression of BMP-2, Runx2 (runt-related transcription factor 2), and OPN (osteopontin) | [ |
|
| hBM-MSC | Osteogenic | Increases expression of ALP, collagen I, osteopontin, and osteocalcin genes | [ |
|
| hBM-MSC | Osteogenic | Increases alkaline phosphatase activity | [ |
| TCM: ZD-I | Telomerized hMSCs | Osteogenic | Increases mRNA expression of ALP, Runx2, and osteocalcin | [ |
|
| hBM-MSC | Osteogenic | Increases transcriptional levels of bone morphogenetic protein 4 (BMP4), runt-related transcription factor 2 (Runx2), | [ |
|
| h BM-MSC | Osteogenic | Enhances Runx2, osteocalcin (OCN), and osteopontin (OPN) expression and activation of the canonical Wnt/ | [ |
|
| hBM-MSC | Neurogenic | Increases expression of mRNA for nestin (a neural precursor marker) and | [ |
|
| hUC-WJ MSCs | Neurogenic | Induces expression of nestin, beta-tubulin III, neurofilament (NF), and glial fibrillary acidic protein (GFAP) | [ |
|
| — | Endothelial/vascular genesis | Increases gene expression for vascular endothelial growth factor, platelet-derived growth factor receptor, and vascular endothelial growth factor receptor (VEGFR)-1 | [ |
|
| hMSC | Osteogenic | Increases expression of alkaline phosphatase activity, osteopontin, Runx2, and osterix and promotes osteogenesis by activating the ERK signaling pathway | [ |
|
| AD-MSCs | Neurogenic | Increases expression of neuron-specific enolase (a specific marker of neurons) | [ |
|
| hM-MSCs | Osteogenic | Increases activity of ALP and the amount of calcified nodules and expression of BMP-2 also increase | [ |
|
| DP-MSCs | Osteogenic | Osteonectin and osteocalcin levels increase | [ |
|
| hBM-MSC | Osteogenic | Osteocalcin, Runx2, BMP2, and ALP gene expression upregulate | [ |
|
| hBM-MSC | Osteogenic | 17 | [ |
|
| h-DP and BM-MSCs | Osteogenic | Osteocalcin (OCN) (late osteogenic marker) level increases | [ |
|
| Wistar rat BM-MSCs | Osteogenic | Increases ALP activity | [ |